Your browser doesn't support javascript.
loading
Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.
Lu, Xiaoxiao; Emond, Bruno; Morrison, Laura; Kinkead, Frederic; Lefebvre, Patrick; Lafeuille, Marie-Hélène; Khan, Wasiulla; Wu, Linda H; Qureshi, Zaina P; Jacobs, Ryan.
Afiliación
  • Lu X; Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
  • Emond B; Health Economics and Outcomes Research, Analysis Group, Inc, Montréal, Québec, Canada.
  • Morrison L; Health Economics and Outcomes Research, Analysis Group, Inc, Montréal, Québec, Canada.
  • Kinkead F; Health Economics and Outcomes Research, Analysis Group, Inc, Montréal, Québec, Canada.
  • Lefebvre P; Health Economics and Outcomes Research, Analysis Group, Inc, Montréal, Québec, Canada.
  • Lafeuille MH; Health Economics and Outcomes Research, Analysis Group, Inc, Montréal, Québec, Canada.
  • Khan W; Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
  • Wu LH; Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
  • Qureshi ZP; Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
  • Jacobs R; Hematology and Medical Oncology, Atrium Health Levine Cancer Institute, Charlotte, NC, USA.
Patient Prefer Adherence ; 17: 2073-2084, 2023.
Article en En | MEDLINE | ID: mdl-37641660

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Patient Prefer Adherence Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Patient Prefer Adherence Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos